Pangea Bio is a clinical-stage biotech company focused on developing transformative medicines for neurological and mental health disorders. The company's core research targets the TrkB receptor pathway to promote neuronal survival and synaptic plasticity. Their lead candidate, OT-003, and subsequent pipeline assets are designed to address significant unmet needs in CNS diseases.
Funding
$20.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological and neuropsychiatric disorders present a significant and growing unmet need, with increasing patient populations and a limited number of effective treatments. Traditional drug discovery methods struggle to efficiently explore the vast chemical diversity of natural compounds for potential therapeutic applications in the central nervous system (CNS).
Solution
Pangea Bio utilizes artificial intelligence to accelerate the discovery and development of novel medicines derived from natural sources for neurological and neuropsychiatric disorders. The company's AI engine analyzes the chemical space of natural compounds, enhanced by evidence of traditional medicinal use, to identify promising molecules with potential efficacy and tolerability in the CNS. This approach enables the development of a scalable pipeline of nature-inspired drug candidates targeting a range of CNS disorders. Their lead asset, OT-003, demonstrates compelling efficacy across neurological disease models, with Phase 1 studies planned.
Target Audience
The primary target audience includes individuals and healthcare providers seeking new treatments for neurological and neuropsychiatric diseases, as well as pharmaceutical companies interested in innovative drug discovery approaches.
Features
- AI-powered drug discovery platform for identifying novel CNS therapeutics from natural sources.
- Focus on nature-inspired compounds with prior human medicinal use as an indicator of efficacy and tolerability.
- Scalable pipeline for a range of CNS disorders.
- Lead asset OT-003 with demonstrated efficacy in neurological disease models.